Compare Teradyne, Inc. (TER) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs TG Therapeutics Inc — how do they compare? Teradyne, Inc. trades at $403 (market cap $62.34B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Teradyne, Inc. is far larger — about 7.6× TG Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and TG Therapeutics Inc for 16 Days on average.
| TER | TGTX | |
|---|---|---|
Market Cap | $62.34B | $8.16B |
Volume | 3,368,404 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $483.84 | $59.06 |
52-Week Low | $132.05 | $26.94 |
Typical Hold Time | 37 Days | 16 Days |
Enterprise Value | $62.08B | $8.37B |
Dividend Yield | 0.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $402.68, down 2.21% on the day, but maintains a bullish technical outlook with strong support near $388. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.47 surpassing the $2.09 estimate. Revenue growth is accelerating, projected to reach $4.5 billion in 2026, while net income margins are expected to expand to 25.76%. Recent developments include the launch of the Magnum E2 memory test system and Iris 100 for microLED devices, positioning TER to capitalize on AI and high-performance computing demand.
The investment outlook for TER is positive, driven by strong fundamentals, analyst optimism, and strategic positioning in semiconductor test equipment. Key opportunities include exposure to AI-driven demand and consistent earnings outperformance. Risks involve competitive pressures from firms like KLAC and COHU, cyclical semiconductor industry dynamics, and execution risks in new product launches. With a consensus price target of $461.50 and no sell ratings, Wall Street sentiment remains bullish, though valuation multiples are elevated.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
